The Prognosis of Acute Myocardial Infarction
AMI-COPS
The Characteristics and Clinical Outcomes of Acute Myocardial Infarction
1 other identifier
observational
7,350
1 country
1
Brief Summary
This study aims to establish a registry and surveillance system for acute myocardial infarction (AMI) patients in Xinjiang, focusing on collecting comprehensive information including basic patient demographics, patient characteristics, diagnostic methods, treatment programs, and hospitalization outcomes such as mortality, treatment complications, hospitalization costs, and follow-up events (death, major adverse cardiac events). The goal is to identify and propose effective prevention strategies to reduce the incidence of AMI, optimize the management and outcomes of AMI patients by implementing guideline recommendations in clinical practice, and conduct analyses to develop effective treatment strategies and predictive models for clinical outcomes. This focus on Xinjiang aims to provide a comprehensive understanding of AMI within this specific geographic and demographic context, ultimately contributing to improved prevention, treatment, and management of AMI patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2012
CompletedFirst Submitted
Initial submission to the registry
April 5, 2016
CompletedFirst Posted
Study publicly available on registry
April 14, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 10, 2023
CompletedMarch 28, 2024
March 1, 2024
4 years
April 5, 2016
March 26, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Death
All-cause mortality, Cardiac mortality
5 years
Secondary Outcomes (3)
Major adverse cardiovascular events (MACE)
5 years
Major adverse cardiovascular and cerebrovascular events (MACCE)
5 years
stroke
5 years
Study Arms (2)
AMI patients with treatment of PCI
All the patiets treat with PCI were enrolled and recorded the clinical characteristic and outcomes during the follow-up period.
Medication
All the patiets treat with medication (standard secondary prevention) without PCI were enrolled and recorded the clinical characteristic and outcomes during the follow-up period.
Eligibility Criteria
The study population consists of acute myocardial infarction (AMI) patients hospitalized at the First Affiliated Hospital of Xinjiang Medical University. This includes individuals diagnosed with both acute ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI).
You may qualify if:
- Acute myocardial infarction patients in hospitalized of the First Affiliated Hospital of Xinjiang Medical University (include diagnosed acute ST-elevation or non ST-elevation myocardial infarction).Diagnosis criteria must meet Universal Definition for AMI (2012).
You may not qualify if:
- Combined with severe valvular heart disease;
- Combined with severe congenital heart disease;
- Combined hyperthyroidism, anemia and other high-powered heart disease;
- With pulmonary heart disease;
- With hypertrophic obstructive cardiomyopathy;
- Severe hypotension (SBP \<90mmHg or DBP \<60mmHg at enrollment);
- Uncontrolled hypertension (SBP\> 160 mmHg before PCI, and / or DBP\> 100 mmHg);
- Liver dysfunction (defined as ALT or total bilirubin is greater than the normal upper limit of 3 times);
- Renal insufficiency (defined as serum creatinine greater than 1.5 times the normal upper limit);
- High-risk bleeding patients, such as thrombocytopenia, blood diseases and other diseases;
- active peptic ulcer and skin ulcers;
- A patient who is allergic to clopidogrel, tegrellol, or aspirin;
- Patients with a history of cardiogenic shock within two weeks;
- pregnant and lactating women, during treatment can not be strict contraception of women of childbearing age;
- In the past 3 months participated in other clinical researchers;
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
First Affilliatted Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, 830011, China
Related Publications (2)
Yan J, Deng CJ, Wang SF, Aimaitijiang M, Wu TT, Zheng YY, Xie X, Ma YT. Predictive Value of the Modified GRACE Scoring System for All-Cause Mortality in Patients with Acute Myocardial Infarction. Rev Cardiovasc Med. 2023 Jun 6;24(6):161. doi: 10.31083/j.rcm2406161. eCollection 2023 Jun.
PMID: 39077519DERIVEDXiu WJ, Yang HT, Zheng YY, Ma YT, Xie X. Delayed PCI 12 Hours after the Onset of Symptoms Is Associated with Improved Outcomes for Patients with ST-Segment Elevation Myocardial Infarction: A Real-World Study. J Interv Cardiol. 2019 Jun 18;2019:2387929. doi: 10.1155/2019/2387929. eCollection 2019.
PMID: 31772517DERIVED
Study Officials
- PRINCIPAL INVESTIGATOR
Xiang Xie, PhD
Xinjiang Medical University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Xiangxie, MD,Professor, The First Affiliated Hospital Of XinJiang Medicial University
Study Record Dates
First Submitted
April 5, 2016
First Posted
April 14, 2016
Study Start
June 1, 2012
Primary Completion
May 31, 2016
Study Completion
December 10, 2023
Last Updated
March 28, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share